Page 42 - ESGO - Vulvar cancer - Complete report_fxd2

Table 11. Original studies included in the meta-analysis published by Stuckey et al.249

Authorreference Year N Median age Chemotherapy Radiotherapy Median follow-up DOD DOT DICD NED
regimen regimen (months) (%) (%) (%) (%)
(years) 5-FU/CisP 40-50 Gy 21 27.3 0.0 9.1 63.6
5-FU± MMC 45-50.4 Gy 36 13.3 0.0 13.1 73.3
Eifel et al.245 1995 11 55 (37-85) 5-FU/CisP 46.64 Gy 34 16.7 0.0 0.0 83.3
Wahlen et al.234 1995 15 64 (37-89) 5-FU/MMC 25-50 Gy 7 57.1 14.3 0.0 28.8
5-FU/MMC 18-60 Gy 5 0.0 0.0 0.0 80.0
Berek et al.237 1991 12 69 (52-76) 5-FU/CisP 43-49 Gy 19.5 0.0 0.0 0.0 100.0
Whitaker et al.246 1990 7 73 (65-87) 5-FU ± CisP 46-72 Gy 17 months 6.3% 6.3 0.0 75.0
Levin et al.247 1986 5 60 (44-66)
Beriwal et al.248 2006 4 66.5 (54-84)
Russel et al.229 1992 16 71 (13-90)

5-FU: 5-fluorouracil, CisP: cisplatin, DICD: dead of intercurrent disease, DOD: dead of disease, DOT: dead of treatment, Gy: Gray, MMC: mitomycin C,
NED: no evidence of disease and no recurrence.

Table 12. Original studies presenting response and survival data in patients treated with adjuvant chemoradiation

Authorreference Year N Chemotherapy regimen Radiotherapy regimen Survival

Mak et al.231 2011 LAVC : N = 10 Either weekly CisP or 3-4 week 5- 50 Gy, timing of fractions varied Median follow-up: 31.5 months

FU based regimens Status: NA

Recurr.: NA

Thomas et al.230 1989 LAVC: N = 9 5-FU 1,000 mg/m² infusion d1-4 ± 40-64 Gy in 1.6-1.8 Gy twice Median follow-up: 21 months

MMC 6 mg/m² (4/6 one injection, daily fractions Status: 78% (7/9) alives NED

and 2/6 two injections 4 weeks apart) Recurr.: 22% (2/7)

Mulayim et al.225 2004 LAVC: N = 6 5-FU 1,000 mg/m² infusion d1-4 and 60 Gy for macro and 45 Gy for Median follow-up: 20 months
21-24 of radiotherapy + MMC 10 microscopic disease Status: 0% (0/6)
mg/m² IV d1 and d21 of Recurr.: 33% (2/6)
radiotherapy

Han et al.236 2000 LAVC: N = 6 5-FU 1,000 mg/m² infusion d1-4 + 40-62 Gy Median follow-up: 17 months
MMC 10 mg/m² IV d1, given week Status: 83% (5/6) alive NED
1 and 5 of radiotherapy Recurr.: 17% (1/6)

5-FU: 5-fluorouracil, CisP: cisplatin, Gy: Gray, LAVC: locally advanced vulvar cancer, MMC: mitomycin C, NA: not available, NED: no evidence of disease
and no recurrence, Recurr.: recurrence.

 VULVAR CANCER - GUIDELINES 
42